Cancer: Types and Hallmarks

  • Madhumita Roy
  • Amitava Datta


We review some of the main characteristics of cancer in this chapter. Our aim is to give the reader a general overview and a molecular biological or genetic understanding of the disease. However, our review is by no means exhaustive, and the interested reader should explore these topics from the references provided at the end of the chapter. We start with explaining cancer as a neoplastic disease and some reasons for its occurrence. Next, we discuss the different categories of cancers depending on the cell types where they originate. This is a convenient categorization as there are many different types of cancers with many common attributes that can be captured through this categorization. Then we discuss some of the major hallmarks of cancer and the current genetic and biochemical understanding of these hallmarks. We explain some of the key genetic pathways that support these hallmarks and also some interconnections between these pathways. Next, we discuss some of the enabling characteristics like genetic mutation and tumor-promoting inflammation that are responsible for the occurrence of cancer. Finally, we conclude the chapter with an overview of symptoms, diagnosis, and different types of treatments of cancer.


  1. 1.
  2. 2.
    L.M. Coussens, Z. Werb, Inflammation and cancer. Nature 420, 860–867 (2010)CrossRefGoogle Scholar
  3. 3.
    L.D. Derycke, M.E. Bracke, N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signaling. Int. J. Dev. Biol. 48(5–6), 463–476 (2004)CrossRefGoogle Scholar
  4. 4.
    D. Hanahan, R.A. Weinberg, Hallmarks of cancer: The next generation. Cell 144, 646–674 (2011)CrossRefGoogle Scholar
  5. 5.
    A.M. Petrilli, C. Fernandez-Valle, Role of Merlin/NF2 inactivation in tumor biology. Oncogene 35(5), 537–548 (2015)CrossRefGoogle Scholar
  6. 6.
    M. Momcilovic, D.B. Shackelford, Targeting LKB1 in cancer – exposing and exploiting vulnerabilities. Br. J. Cancer 113, 574–584 (2015)CrossRefGoogle Scholar
  7. 7.
    A.F. Hezel, N. Bardeesy, LKB1: Linking cell structure and tumor suppression. Oncogene 27, 6908–6919 (2008)CrossRefGoogle Scholar
  8. 8.
    A. Shamas-Din, H. Brahmbhatt, B. Leber, D.W. Andrews, BH3-only proteins: Orchestrators of apoptosis. Biochim. Biophys. Acta 1813(4), 508–520 (2010)CrossRefGoogle Scholar
  9. 9.
    R.J. Youle, A. Strasser, The BCL-2 protein family: Opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9, 47–59 (2008)CrossRefGoogle Scholar
  10. 10.
    Y. Liu, M. Kulesz-Martin, p53 protein at the hub of cellular DNA damage response pathways through sequence-specific and non-sequence-specific DNA binding. Carcinogenesis 22(6), 851–860 (2001)CrossRefGoogle Scholar
  11. 11.
    J.S. Fridman, S.W. Lowe, Control of apoptosis by p53. Oncogene 22(56), 9030–9040 (2003)CrossRefGoogle Scholar
  12. 12.
    M.E. Peter, A. Hadji, A.E. Murmann, S. Brockway, W. Putzbach, A. Pattanayak, P. Ceppi, The role of CD95 and CD95 ligand in cancer. Cell Death Differ. 22, 549–559 (2015)CrossRefGoogle Scholar
  13. 13.
    E.H. Blackburn, J.W. Szostak, The molecular structure of centromeres and telomeres. Annu. Rev. Biochem. 53, 163–194 (1984)CrossRefGoogle Scholar
  14. 14.
    J.A. Nagy, S.-H. Chang, S.-C. Shih, A.M. Dvorak, H.F. Dvorak, Heterogeneity of the tumor vasculature. Semin. Thromb. Hemost. 36(3), 321–331 (2012)CrossRefGoogle Scholar
  15. 15.
    S. Heerboth, G. Housman, M. Leary, M. Longacre, S. Byler, K. Lapinska, A. Willbanks, S. Sarkar, EMT and tumor metastasis. Clin. Transl. Med. 4(6) (2015).
  16. 16.
    N. Hay, Reprogramming glucose metabolism in cancer: Can it be exploited for cancer therapy? Nat. Rev. Cancer 16, 635–649 (2016)CrossRefGoogle Scholar
  17. 17.
    R.G. Jones, C.B. Thompson, Tumor suppressors and cell metabolism: A recipe for cancer growth. Genes Dev. 23, 537–548 (2009)CrossRefGoogle Scholar
  18. 18.
    C.M. Vajdic, M.T. van Leeuwen, Cancer incidence and risk factors after solid organ transplantation. Int. J. Cancer 125, 1747–1754 (2009)CrossRefGoogle Scholar
  19. 19.
    J. van Riggelen, A. Yetil, D.W. Felsher, MYC as a regulator of ribosome biogenesis and protein synthesis. Nat. Rev. Cancer 10, 301–309 (2010)CrossRefGoogle Scholar
  20. 20.
    J.J. Salk, E.J. Fox, L.A. Loeb, Mutational heterogeneity in human cancers : Origin and consequences. Ann. Rev. Pathol. 5, 51–75 (2010)CrossRefGoogle Scholar
  21. 21.
    S. Negrini, V.G. Gorgoulis, T.D. Halazonetis, Genomic instability – an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol. 11, 220–228 (2010)CrossRefGoogle Scholar
  22. 22.
    R. Jaenisch, A. Bird, Epigenetic regulation of gene expression: How the genome integrates intrinsic and environmental signals. Nat. Genet. Suppl. 33, 245–254 (2003)CrossRefGoogle Scholar
  23. 23.
    S.I. Grivennikov, F.R. Greten, M. Karin, Immunity, inflammation, and cancer. Cell 140, 883–899 (2010)CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Madhumita Roy
    • 1
  • Amitava Datta
    • 2
  1. 1.Environmental Carcinogenesis and ToxicologyChittaranjan National Cancer InstituteKolkataIndia
  2. 2.Department of Computer Science and Software EngineeringThe University of Western AustraliaPerthAustralia

Personalised recommendations